We demonstrate that the multipeptide KRAS vaccine is immunogenic and efficacious in the primary prevention of KRAS-induced lung cancer, indicating that the approach potentially can be used to prevent other KRAS-driven cancers, either alone or in combination with other modalities. Here, KRAS is linked to lung carcinoma.